Pharmaceutical Executive
Doctors and academics are praising Pfizer’s plan to allow the Cleveland Clinic to compare Celebrex with two NSAIDs. Is the company courageous, or is it taking to big of a risk?
Pharmaceutical Executive-12-21-2005
Pharmaceutical Executive
A recent spate of false positive results using OraSure’s test has officials and company representatives scrambling to figure out what is causing these anomalies and how to stop them from impacting testing rates.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
